Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

You must log in to access content on this page. Or click here to request access.
Our goal is to create measurable differences in global health.

MediBeacon is a medical technology company focused on advancing the use of fluorescent tracer agents and transdermal detection technology to provide vital and actionable measurement of organ function. New insights that have direct relevance to treatment decisions are the goal.

Accurate physiological measurements made in real-time, are vital in the hospital as well as in the management of chronic diseases. The opportunities to use this data to help improve disease treatments in situations where multiple unknowns make clinical decisions a challenge are vast.

In October of 2018 the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). The device is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function.

TGFR Phase 3 study enrollment has been completed.
MediBeacon products are in various stages of clinical development and are not yet approved for human use.
First in-human clinical studies are underway to establish the feasibility of fluorescent tracer agent-based systems to quantify the permeability of the gastrointestinal tract in patients with active Crohn’s Disease.
Maintenance of intestinal barrier function is important for our health, and dysfunction is a risk factor for a variety of disorders and diseases.
- Clinical and Translational Gastroenterology, Julia König et al., Human intestinal barrier function in health and disease, September 14, 2016

Accurate physiological measurements made in real-time and at the point of care could be of utmost value in the hospital as well as in the management of chronic diseases. Fluorescent tracer agent-based monitoring systems are well positioned to provide an indication of GFR, quantification of GI permeability, enhanced visualization of the vasculature during ocular angiography, and identification of the ureters during abdominal surgeries.*

At MediBeacon we strive to create measurable differences that impact global health. Evidence of our advances can be found in the numerous issued global patents.
MediBeacon developments have been the subject of numerous publications including peer-reviewed and proceedings papers, as well as review articles and posters presented at global scientific conferences.
Transdermal measurement of Glomerular Filtration Rate (tGFR) is well established in preclinical research. MediBeacon technology is used by leading medical schools, academic centers, research institutes, contract research organizations and pharmaceutical companies worldwide to enhance preclinical assessment of kidney therapeutics, evaluate nephrotoxicity, and gain fundamental understanding of kidney function in animals.